Lexeo Therapeutics Inc(LXEO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.16 | Insider Own | 15.83% | Shs Outstand | 78.6M | Perf Week | 4.33% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | -12.34% | Insider Trans | -0.54% | Shs Float | 69.1M | Perf Month | -8.48% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.32 | Inst Own | 100.05% | Short Float | 25.41% | Perf Quarter | -28.05% |
| Income | -0.09B | P/S | - | EPS this Y | 36.08% | Inst Trans | 7.51% | Short Ratio | 13.76 | Perf Half Y | -44.89% |
| Sales | 0.00B | P/B | 1.05 | EPS next 5Y | 13.49% | ROA | -40.5% | Short Interest | 17.55M | Perf YTD | -68.48% |
| Book/sh | 2.99 | P/C | 1.21 | EPS past 3/5Y | 5.73% -57.31% | ROE | -46.76% | 52W High | -71.52% ($10.99) | Perf Year | -68.95% |
| Cash/sh | 2.58 | P/FCF | - | Sales past 3/5Y | - | ROIC | -36.48% | 52W Low | 22.75% ($2.55) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 64.51% | Gross Margin | - | Volatility(W/M) | 7.39% 8.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.89 | EPS Q/Q | 49.57% | Profit Margin | - | RSI (14) | 47.66 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.89 | Sales Q/Q | - | SMA20 | 3.32% ($3.03) | Beta | 1.66 | Target Price | $20.67 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/12 | SMA50 | -18.41% ($3.84) | Rel Volume | 0.94 | Prev Close | $2.87 |
| Employees | 59 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -5.19% - | SMA200 | -40.45% ($5.26) | Avg Volume(3M) | 1.28M | Price | $3.13 |
| IPO | 2023/11/3 | Option/Short | Yes/Yes | Trades | 7042 | Volume | 1,196,207 | Change | 9.06% |
🧬 Lexeo Therapeutics (LXEO) is a clinical-stage biotech company developing adeno-associated virus (AAV)-based gene therapies targeting inherited cardiac diseases. Headquartered in the United States, the company is focused on a pipeline of rare hereditary heart conditions, including Friedreich's ataxia cardiomyopathy and gene variant-associated arrhythmic cardiomyopathy.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
LXEO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +36.1% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.4% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #282 of 594 in the industry
Based on market cap of $257M.
IMRX#280 Immuneering Corp $259M PER - 
CABA#281 Cabaletta Bio Inc $258M PER - LXEO#282 Lexeo Therapeutics Inc $257M PER - 
CUVL#283 Clinuvel Pharmaceuticals Ltd ADR $256M PER 11.0 
IFRX#284 InflaRx NV $255M PER - 
FAQ
What kind of company is LXEO?
LXEO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LXEO?
The market cap of LXEO is approximately $257M, ranking 3,818 within its sector.
What is the 52-week high and low for LXEO?
LXEO has recorded a 52-week high of $10.99 and a low of $2.55.
